Drs Peter Martin and Michael Wang discuss the role of CAR T cells in mantle cell lymphoma, how they are used with respect to bridging therapy, and the surveillance and management of toxicities.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/982891). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Mantle Cell Lymphoma https://emedicine.medscape.com/article/203085-overview

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/32242358/

Three-Year Follow-up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study https://pubmed.ncbi.nlm.nih.gov/35658525/

Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real World Experience From the US Lymphoma CAR T Consortium https://ashpublications.org/blood/article/138/Supplement%201/744/479986/Brexucabtagene-Autoleucel-for-Relapsed-Refractory

Real-World Evidence of Brexucabtagene Autoleucel for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/35271707/

Frequency of Gastrointestinal Involvement and Its Clinical Significance in Mantle Cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/12548600/

Society for Immunotherapy of Cancer (SITC) Clinical Practice Guideline on Immune Effector Cell-Related Adverse Events https://pubmed.ncbi.nlm.nih.gov/33335028/

Management of a Patient With Mantle Cell Lymphoma Who Developed Severe Neurotoxicity After Chimeric Antigen Receptor T-cell Therapy in ZUMA-2 https://pubmed.ncbi.nlm.nih.gov/33067318/

Experiences With Glofitamab Administration Following CAR T Therapy in Patients With Relapsed Mantle Cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/36078155/

Glofitamab Monotherapy Induces High Complete Response Rates in Patients With Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma https://ash.confex.com/ash/2022/webprogram/Paper157777.html

GEN3013, Epcoritamab Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma EPCORE™ NHL-1 https://www.clinicaltrials.gov/ct2/show/NCT03625037